Glow70 & Klow80 Research Guide: Triple & Quad Peptide Tissue Repair Blends (GHK-Cu, BPC-157, TB-500, KPV)

Glow70 and Klow80 are proprietary multi-peptide injectable research formulations developed by Exceed Enhancement that combine synergistic tissue-repair and regenerative peptides into a single preparation. Glow70 delivers three peptides, GHK-Cu, BPC-157, and TB-500, while Klow80 extends this with the addition of KPV, creating a quad-peptide research compound. Both formulations target overlapping but complementary biological pathways: copper-mediated tissue remodeling, gut-to-systemic healing, extracellular matrix repair, and anti-inflammatory resolution. This guide covers the science behind each component and the rationale for their combination. All content is for informational and research purposes only.

Glow70: Triple Peptide Tissue Repair Blend

Formulation

Each ml of Glow70 contains:

• GHK-Cu (Copper Tripeptide-1), 50 mg/ml
• BPC-157, 10 mg/ml
• TB-500 (Thymosin Beta-4), 10 mg/ml

GHK-Cu: Copper Tripeptide Matrix Remodeler

GHK-Cu (Gly-His-Lys + Cu²⁺) is the dominant bioactive copper-binding tripeptide in human plasma. At physiological concentrations it acts as a potent activator of tissue remodeling through multiple mechanisms: it upregulates collagen, elastin, and glycosaminoglycan synthesis while simultaneously activating matrix metalloproteinases (MMPs) to remove damaged extracellular matrix, effectively orchestrating wound debridement and structural rebuilding in sequence. GHK-Cu also activates the Nrf2 antioxidant pathway, upregulating over 30 antioxidant and anti-inflammatory genes, and has demonstrated significant effects on skin fibroblast gene expression across 31 of the 84 genes identified in wound healing arrays. At 50 mg/ml, the highest concentration component in Glow70, GHK-Cu provides the dominant matrix-remodeling and antioxidant framework of the blend.

BPC-157: Systemic Healing and Angiogenesis Driver

BPC-157 (Body Protection Compound-157) is a stable pentadecapeptide derived from a protective gastric protein. Its mechanisms are unusually broad, operating through nitric oxide (NO) system modulation, VEGF-driven angiogenesis, and upregulation of growth factor receptors (EGF-R, FGFR2) at injury sites. BPC-157 accelerates healing of tendons, muscle, bone, gut epithelium, cornea, and nerve tissue in preclinical models. The 10 mg/ml concentration in Glow70 provides targeted angiogenic and tissue-growth factor signaling that complements GHK-Cu’s structural remodeling activity, new vasculature supports delivery of oxygen and nutrients to the remodeling extracellular matrix.

TB-500: Actin Cytoskeletal Repair and Cell Migration

TB-500 (Thymosin Beta-4 synthetic fragment) promotes cell migration and tissue repair primarily by sequestering G-actin, increasing the pool of actin available for cytoskeletal remodeling and enabling satellite cells, fibroblasts, and endothelial cells to migrate into injury zones. TB-500 also activates Akt/PI3K survival signaling, reduces inflammatory cytokines (IL-6, TNF-α), and promotes differentiation of progenitor cells at wound sites. At 10 mg/ml in Glow70, TB-500 provides cellular mobilization capacity that drives the repopulation of tissue scaffolds generated by GHK-Cu and the vascular supply built by BPC-157.

Synergistic Rationale for Glow70

The three components of Glow70 address sequential phases of tissue repair:

• Phase 1, Matrix preparation: GHK-Cu activates MMPs to clear damaged ECM while simultaneously stimulating new collagen and elastin deposition
• Phase 2, Vascular supply: BPC-157’s VEGF-driven angiogenesis establishes the blood supply needed to sustain active tissue regeneration
• Phase 3, Cell recruitment and differentiation: TB-500 drives migration of progenitor and repair cells into the remodeling zone and promotes their differentiation into mature tissue-specific cells

Research interest in multi-peptide combinations reflects growing understanding that wound healing is a coordinated multicellular, multiphase process, and that single-agent interventions address only one facet of this complexity. The GHK-Cu + BPC-157 + TB-500 combination targets ECM, vascular, and cellular repair axes simultaneously.

Klow80: Quad Peptide Blend with KPV

Formulation

Each ml of Klow80 contains:

• GHK-Cu, 50 mg/ml
• BPC-157, 10 mg/ml
• TB-500, 10 mg/ml
• KPV, 10 mg/ml

KPV: Anti-Inflammatory Alpha-MSH C-Terminal Fragment

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), a three-amino acid fragment that retains the anti-inflammatory and immunomodulatory properties of the full α-MSH molecule. KPV exerts its effects primarily through:

• NF-κB inhibition: KPV directly inhibits NF-κB nuclear translocation and reduces transcription of pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and IL-8, the canonical drivers of chronic inflammatory tissue damage
• MC1R and MC3R agonism: KPV activates melanocortin receptors on immune cells and epithelial cells, triggering cAMP-mediated anti-inflammatory signaling cascades
• Gut epithelial protection: KPV has demonstrated particular efficacy in intestinal inflammation models, reducing colitis severity, restoring tight junction proteins (ZO-1, occludin), and decreasing mucosal inflammatory infiltrate in IBD models
• Wound healing enhancement: KPV promotes keratinocyte migration and reduces inflammatory phase duration, accelerating transition to the proliferative repair phase

Extended Rationale: Why Klow80 Adds KPV

Chronic inflammation is both a driver and a consequence of inadequate tissue repair. While the GHK-Cu + BPC-157 + TB-500 triad in Glow70 addresses structural, vascular, and cellular repair mechanisms, unresolved inflammatory signaling can continue to recruit immune cells and generate ROS that counteract remodeling progress. KPV’s addition to Klow80 provides direct NF-κB and cytokine suppression, addressing the inflammatory microenvironment that can impede the regenerative actions of the other three components.

This makes Klow80 particularly relevant for research in settings of significant inflammatory burden: inflammatory bowel disease, chronic wound research, autoimmune-related tissue damage, or post-surgical healing where inflammation is a dominant feature rather than a brief acute phase.

Glow70 vs. Klow80: When Each May Be Relevant

Research and Storage Notes

Both Glow70 and Klow80 are lyophilized multi-peptide preparations supplied as sterile powder requiring reconstitution with bacteriostatic water prior to use. Each component peptide should maintain ≥98% HPLC purity with mass spectrometry confirmation in the final blend. Storage of lyophilized preparations: -20°C, protected from light and moisture. Reconstituted solution: 2–8°C, use within 28 days. As with all multi-component research preparations, independent stability and compatibility data for the specific combination should be reviewed from the supplier’s quality documentation.

Disclaimer

Glow70 and Klow80 are proprietary research peptide formulations sold strictly for in vitro and preclinical research purposes. They are not approved drug products and are not intended for human therapeutic use. This content is for educational and scientific informational purposes only and does not constitute medical advice.

References

• Pickart L, Margolina A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 19(7), 1987.
• Sikiric P, et al. (2018). Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design, 24(18), 1938–1956.
• Goldstein AL, Hannappel E, Kleinman HK. (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429.
• Dalmasso G, et al. (2008). The peptide KPV inhibits NF-κB-dependent inflammatory responses in intestinal epithelial cells. Gastroenterology, 135(2), 399–412.
• Brzoska T, Luger TA, Maaser C. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: anti-inflammatory mechanisms. Endocrine Reviews, 29(5), 581–602.

Research-Grade Products Available

• Klow80 →
• Glow70 →